Niraparib..........

In the US, the Food and Drug Administration has approved niraparib (Zejula) for maintenance after front line chemo for advanced-Stage OC.

This PARP is approved for platinum-sensitive women who don’t have inherited BRCA mutations or tumours as well as those who do.

Lets hope other countries follow very soon.

[Flamingobeef18]

That is good news for those in the US.

I wonder whether the overall eligibility criteria is similar to the criteria here through the NHS Cancer Fund?

Juliax

[SUE7777]

As far as I know we can get it in the UK. Sue x

[Hidden in reply to SUE7777]

yes you can, but only after 1st recurrence, the new proposal in the US is to make it available after initial first treatment as maintenance.

[SUE7777 in reply to Hidden]

Yes you only get Parp Inhibitors for first line if your BRACA positive, otherwise it's Avastin. I'm BRACA negative so am getting Avastin as maintenence.

[Mptelesca]

That is great news! I was told that the average reoccurrence happens at three years. It will be interesting if zejula can extend that time. I have been on zejula since October 2018. After my first recurrence since diagnosis in 2015.

Thanks for sharing that!

Xox

Marisa

[Cbyrdie]

Marisa,

Are you BRCA neg? Are you in US or U.K.? I just finished round 9 of carbo/taxol after first reoccurrence. I was 4+ years NED

[Jane420]

The parbs are prescribed in the states also for Brac negative women who are hrd positive .